The Department of Health Services (DHCS) releases monthly Drug Utilization Review (DUR) articles which provide timely and relevant information impacting providers and their patients. L.A. Care is sharing the latest release from June on sleep aids.
Drug Safety Communication: Sleep Behavior Risks with Select Sleep Aids
Released June 28, 2019
On April 30, the U.S. Food and Drug Administration (FDA) announced they are requiring safety label changes for eszopiclone, zaleplon, and zolpidem because of the risk of complex sleep behaviors.
These behaviors include sleepwalking, sleep driving, and engaging in other activities while not fully awake.
View the Drug Safety Communication: Sleep Behavior Risks with Select Sleep Aids article (dured_27983).